Vtama (tapinarof) / Japan Tobacco, Guanhao Biotech, Organon - LARVOL DELTA

Tapinarof Nanogels as a Promising Therapeutic Approach. (PubMed, Pharmaceutics) - "Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment."

Journal • Review • Dermatology • Immunology • Inflammation • Psoriasis

New Treatments in Atopic Dermatitis Update. (PubMed, Ann Allergy Asthma Immunol) - "Non-steroidal topical treatments, such as roflumilast and tapinarof creams, are approved for adults and children down to 6 and 2 years, respectively. Topical Janus kinase (JAK) inhibitors, including ruxolitinib, leverage inhibition of the JAK1 pathway with low concern for toxicity. The use of biologics targeting the interleukin (IL)-4/IL-13 pathway has expanded; dupilumab is approved for patients 6 months and older and tralokinumab and lebrikizumab are approved for 12 years and above. Most recently, nemolizumab, targeting the IL-31 receptor, which mediates nonhistaminergic itch, has been approved for those 12 years and above. Although baricitinib is approved in Europe and Japan, upadacitinib and abrocitinib remain the only oral JAK inhibitors approved for U.S. patients 12 years and older...These innovations represent a shift toward personalized AD management. As the treatment landscape evolves, ongoing research is essential to assess long-term safety and efficacy, as..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • IL13 • JAK1 • TNFSF4

Focused update: Guidelines of care for the management of atopic dermatitis in adults. (PubMed, J Am Acad Dermatol) - "The workgroup developed strong recommendations for the use of tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab with concomitant topical therapy."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The AhR Agonist Tapinarof Suppresses Human Skin Inflammation by Inducing Metabolic Reprogramming and Reducing Production of Mitochondrial Pro-inflammatory DAMPs (FOCIS 2025) - "Finally, tapinarof disrupted mitochondrial function, by reduced mitochondrial membrane potential and mitochondrial mass, suggesting a decrease in mitochondrial fitness. In summary, tapinarof acts at the level of the mitochondria to reduce DAMP sensing via reduced ROS production and mtDNA release, thus markedly reducing inflammatory tone, and by blocking multiple metabolic pathways and impairing mitochondrial function, thus blocking the cells' ability to use and generate energy in the hypoxic skin microenvironment."

Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Psoriasis • HIF1A • mTOR • STING

Off-Label Uses of Topical Tapinarof 1% in Dermatology: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal • Dermatology

Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database. (PubMed, Arch Dermatol Res) - "Tapinarof is generally well tolerated in adults, particularly for psoriasis treatment, but is associated with strong cutaneous and immune-related AE signals. Novel findings-including pharyngeal swelling and tumor-related events-warrant heightened clinical vigilance, especially in patients requiring long-term or large-area application. Gender differences in AE reporting further underscore the need for personalized risk management strategies. Further longitudinal and mechanistic studies are essential to confirm these associations and guide safer clinical use."

Adverse events • Journal • Retrospective data • Acne Vulgaris • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Non-melanoma Skin Cancer • Oncology • Psoriasis • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Computational discovery of novel aryl hydrocarbon receptor modulators for psoriasis therapy. (PubMed, Sci Rep) - "Tapinarof, an AhR agonist recently approved for psoriasis treatment, exerts its action through antioxidant, anti-inflammatory and barrier-restoring effects...Notably, several identified compounds suggest a possible interplay between AhR signaling and sirtuin modulation, highlighting a previously unexplored avenue in psoriasis therapy. Our findings underscore the potential of computational approaches in accelerating the discovery of novel AhR-targeting agents and provide a foundation for further experimental validation."

Journal • Dermatology • Immunology • Inflammation • Psoriasis

Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis. (PubMed, J Drugs Dermatol) - "Tapinarof demonstrated rapid and clinically meaningful pruritus relief in patients with AD, with improvements starting 24 hours after initial application and statistically significant improvements at day 2."

Clinical • Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Therapeutic and microbial aryl hydrocarbon receptor ligands regulate epidermal ceramide biosynthesis (SID 2025) - "The aryl hydrocarbon receptor (AHR) is a transcription factor activated by the agonist tapinarof, an approved topical treatment for plaque psoriasis...Moreover, the increase of ceramides in response to AHR agonists is likely regulated by the AHR, in part, at the level of transcription. Thus, activation of the AHR provides a mechanism for modulating epidermal ceramide levels and provides pharmacological insights into therapeutic and cosmetic applications of AHR ligands."

Dermatology • Immunology • Metabolic Disorders • Psoriasis • CERS3 • CLU • SPTSSB

Efficacy, tolerability, and accessibility of tapinarof cream 1% in the treatment of atopic dermatitis: Case series (SID 2025) - "The sample size limited to 14 patients within Los Angeles, California. Tapinarof cream 1% once daily shows significant clinical improvement given 13 of 14 patients exhibit significant improvement."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Itching control and long-term remission of atopic dermatitis by TAP1503 (SID 2025) - "During the extended follow-up, approximately 70% of participants in the experimental group did not experience any AD flare-ups after discontinuing treatment, up to the 52-week endpoint. In conclusion, this first and only study in China to use tapinarof (TAP1503) for treating AD-associated pruritus and examining its long-term effects demonstrates that it provides rapid relief and may extend the duration of remission."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • TAP1

Successful bimekizumab treatment for palmoplantar psoriasis in skin of color (SID 2025) - "He failed multiple treatments, including topical therapies (triamcinolone .1%, clobetasol .05%, tapinarof, roflumilast), biologics (secukinumab, adalimumab), and four prednisone courses, which provided temporary relief but led to rebound flares once tapered. This patient's response to bimekizumab underscores the value of targeting immune pathways in refractory cases and the risks of long-term corticosteroid use. Bimekizumab offers a promising option for refractory PPP, providing symptom relief and a strong safety profile, especially for patients with skin of color who may have unique immune risks."

Cardiovascular • Coronary Artery Disease • Dermatology • Diabetes • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders • Pain • Pruritus • Psoriasis • Type 2 Diabetes Mellitus • IL17A

Dissecting key contributions of Th2 and Th17 cytokines to atopic dermatitis pathophysiology. (PubMed, J Allergy Clin Immunol) - "Our results reveal the important role of IL-22 in the Th2 driven acute AD pathophysiology and highlight the potential of combinatory medicine in targeted treatment of AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • AKR1C3 • IL13 • IL17A • IL22

Complete Resolution of Residual Psoriasis by Adding Tapinarof Cream to Tildrakizumab: A Case Report. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. (PubMed, J Am Acad Dermatol) - "Tapinarof was well tolerated and resulted in high skin clearance rates that were maintained off-therapy and consistent safety in patients down to age 2 years."

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Respiratory Diseases

The AhR agonist tapinarof suppresses human skin inflammation by inducing metabolic reprogramming and reducing production of mitochondrial pro-inflammatory DAMPs (IMMUNOLOGY 2025) - "Tapinarof-induced AhR signaling reduced HIF1α and mTOR expression in T cells, limiting glucose uptake, glycolytic capacity, and FA metabolism, while also impairing mitochondrial respiration and ATP production, producing marked metabolic dysfunction. In summary, tapinarof acts at the level of the mitochondria to reduce DAMP sensing via reduced ROS production and mtDNA release, thus markedly reducing inflammatory tone, and by blocking multiple metabolic pathways, thus blocking the cells' ability to use and generate energy in the hypoxic skin microenvironment.Keywords: Animals Human; Cells T Cells; Processes Inflammation; Tissues Skin"

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Metabolic Disorders • Psoriasis • HIF1A • mTOR • STING

EQ504: A Potent Derivative of the AhR Ligand ITE Demonstrates Efficacy in Modulating Inflammation and Promoting Healing in DSS-Colitis (IMMUNOLOGY 2025) - "EQ504 demonstrated superior potency compared to other AhR ligands, with similar efficacy to tapinarof, an FDA-approved AhR topical treatment. In an acute DSS colitis model, EQ504 (1 mg/kg) significantly alleviated clinical symptoms, including body weight loss, colon length reduction, and tissue pathology. These findings highlight the therapeutic potential of EQ504 in treating gut inflammation by modulating immune responses and enhancing tissue repair.Keywords: Animals Rodent; Diseases Autoimmunity; Molecules Transcription Factors; Processes Gene Regulation"

Clinical • Late-breaking abstract • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • AHR • IL10 • IL22

Tapinarof for Cutaneous Lupus Erythematosus (clinicaltrials.gov) - P1 | N=10 | Enrolling by invitation | Sponsor: Northwestern University | Not yet recruiting ➔ Enrolling by invitation | Initiation date: Dec 2024 ➔ Apr 2025

Enrollment open • Trial initiation date • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Targeting the Aryl Hydrocarbon Receptor to Attenuate IGF1R Signaling in Thyroid Eye Disease. (PubMed, Thyroid) - "OFs were treated with the AHR ligands 6-formylindolo[3,2-b]carbazole (FICZ) or tapinarof with or without IGF1...Through modulation of GSK3β-mediated pathways, AHR activation may target additional pathologically relevant pathways beyond those affected by direct IGF1R inhibitors. This research provides novel insights into TED pathophysiology and offers a potential avenue for developing therapies to improve patient outcomes."

Journal • Fibrosis • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • AHR • CRABP2 • IGF1R • IRS2 • SOD3 • TUBA1B • TUBA1C

The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation. (PubMed, Nat Rev Drug Discov) - "Indeed, the first AHR-activating drug (tapinarof) was recently approved for the treatment of psoriasis...This Review outlines the molecular mechanism of AHR action, and describes how it regulates the immune response. We also discuss links to disease and AHR-targeting therapeutics that have been tested in past and ongoing clinical trials."

Journal • Review • Dermatology • Immune Modulation • Immunology • Infectious Disease • Oncology • Psoriasis

Health Canada Approves NDUVRA (Tapinarof Cream), 1%, for the Topical Treatment of Plaque Psoriasis in Adults (Canada Newswire) - "Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the first in a novel class of aryl hydrocarbon receptor agonists to be approved in Canada, for the topical treatment of plaque psoriasis in adults....The approval of NDUVRA is based on the results from two randomized, double-blind, multicenter, vehicle-controlled trials conducted to evaluate the safety and efficacy of tapinarof cream for the treatment of adults with plaque psoriasis (symptoms varying from mild to severe)."

Canada approval • Psoriasis

Safety and Efficacy of Non-Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. (PubMed, Australas J Dermatol) - "Our findings support the efficacy of TAHRA among different metrics with minimal and tolerable AEs and its use as a valuable new non-steroidal option for the treatment of AD."

Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA (tapinarof) with Enhanced Therapeutic and Market Extension Prospects (GlobeNewswire) - "Conduit Pharmaceuticals Inc...today announces the filing of two groundbreaking patents for tapinarof (VTAMA), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.... This comes at a critical juncture for VTAMA, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent generic competition upon exclusivity expiry in 2027."

Patent • Atopic Dermatitis • Psoriasis

A Multicenter Study on the Impact of Long-Term and Proactive Intermittent Maintenance Treatment with Benvitimod on Psoriasis Recurrence (ChiCTR) - P4 | N=120 | Not yet recruiting | Sponsor: Peking University Third Hospital; Peking University Third Hospital

New P4 trial • Dermatology • Immunology • Psoriasis

Real world study of Benvitimod cream in the treatment of chronic simple lichen (ChiCTR) - P4 | N=80 | Recruiting | Sponsor: Taizhou Central Hospital; Taizhou Central Hospital

New P4 trial